Skip to main content
SpringerLink
Log in

Breast Cancer

  • Chapter
  • First Online:
Fertility Preservation in Oncological and Non-Oncological Diseases

  • 326 Accesses

Abstract

Breast cancer is the most common cancer in young women. Fortunately, the survival rates are very high, especially in the early stages. Chemotherapy can lead to amenorrhea and infertility, especially in women >30 years of age. The most common chemotherapies impose a significant risk of premature ovarian insufficiency, especially in women >30 years of age. In these women GnRH agonists, freezing of oocytes and freezing of ovarian tissue alone or in combination are options to preserve fertility. If ovarian stimulation is chosen, aromatase inhibitors should be added in estrogen-sensitive cancer to reduce estrogen blood concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schüring AN, Bruckner T, Germeyer A. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reprod Biomed Online. 2015;31:605–12.

    Article  Google Scholar 

  2. Azim HA Jr, Partridge AH. Biology of breast cancer in young women. Breast Cancer Res. 2014;4:427.

    Article  Google Scholar 

  3. Gnerlich JL, Deshpande AD, Jeffe DB, Sweet A, White N, Margenthaler JA. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg. 2009;208:341–7.

    Article  Google Scholar 

  4. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS One. 2009;4:e7695.

    Article  CAS  Google Scholar 

  5. Han W, Kang SY. Korean Breast Cancer Society. Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Clin Breast Cancer Res Treat. 2010;119:193–200.

    Article  Google Scholar 

  6. Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res. 2012;18:1341–51.

    Article  CAS  Google Scholar 

  7. Thomas A, Anthony R, Pinkerton E, Schroeder MC, Conway KM, Hundley G, LR MN, Oleson J, Lynch CH, Romitti P. Incidence and survival among young women with Stage I-III breast cancer: SEER 2000–2015. JNCI Cancer Spectr. 2019;7:pkz040.

    Article  Google Scholar 

  8. Goldhirsch A, Gelber RD, Castiglione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients: the International Breast Cancer Study Group. Ann Oncol. 1990;1:183–8.

    Article  CAS  Google Scholar 

  9. Waks AG, Partridge AH. Fertility preservation in patients with breast cancer: necessity, methods, and safety. J Natl Compr Cancer Netw. 2016;14:355–63.

    Article  CAS  Google Scholar 

  10. Curtin JP, Barakat RR, Hoskins WJ. Ovarian disease in women with breast cancer. Obstet Gynecol. 1994;84:449–52.

    PubMed  CAS  Google Scholar 

  11. Harris M, Howell A, Chrissohou M, Swindell RI, Hudson M, Sellwood RA. A comparison of the metastatic pattern of infiltrating lobular carcinoma and infiltrating duct carcinoma of the breast. Br J Cancer. 1984;50:23–30.

    Article  CAS  Google Scholar 

  12. Sánchez-Serrano M, Novella-Maestre E, Roselló-Sastre E, Camarasa N, Teruel J, Pellicer A. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod. 2009;24:2238–43.

    Article  Google Scholar 

  13. Rosendahl M, Timmermans Wielenga V, Nedergaard L, Kristensen SG, Ernst E, Rasmussen PE, Anderson M, Schmidt KT, Andersen CY. Cryopreservation of ovarian tissue for fertility preservation: no evidence of malignant cell contamination in ovarian tissue from patients with breast cancer. Fertil Steril. 2011;95:2158–61.

    Article  Google Scholar 

  14. Hoekman EJ, Smit VT, Fleming TP, Louwe LA, Fleuren GJ, Hilders CG. Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach. Fertil Steril. 2015;103:469–77.

    Article  Google Scholar 

  15. Bougie O, Weberpals JI. Clinical considerations of BRCA1- and BRCA2-mutation carriers: a review. Int J Surg Oncol. 2011;2011:374012.

    PubMed  PubMed Central  CAS  Google Scholar 

  16. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58–64.

    Article  CAS  Google Scholar 

  17. von Wolff M, Bruckner T, Strowitzki T, Germeyer A. Fertility preservation: ovarian response to freeze oocytes is not affected by different malignant diseases - an analysis of 992 stimulations. J Assist Reprod Genet. 2018;35:1713–9.

    Article  Google Scholar 

  18. Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, Broekmans F, Dreesen JCFM, Paulussen ADC, Tjan-Heijnen VCG, Homminga I, van den Berg MMJ, Ausems MGEM, de Rycke M, de Die-Smulders CEM, Verpoest W, van Golde R. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet. 2017;34:1475–82.

    Article  CAS  Google Scholar 

  19. Turan V, Bedoschi G, Emirdar V, Moy F, Oktay K. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci. 2018;25:26–32.

    Article  CAS  Google Scholar 

  20. Son KA, Lee DY, Choi D. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. Association of BRCA mutations and anti-müllerian hormone level in young breast cancer patients. Front Endocrinol (Lausanne). 2019;10:235.

    Article  Google Scholar 

  21. Regan MM, Walley BA, Francis PA, Fleming GF, Láng I, Gómez HL, Colleoni M, Tondini C, Pinotti G, Salim M, Spazzapan S, Parmar V, Ruhstaller T, Abdi EA, Gelber RD, Coates AS, Goldhirsch A, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017;28:2225–32.

    Article  CAS  Google Scholar 

  22. Bernhard J, Luo W, Ribi K, Colleoni M, Burstein HJ, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Puglisi F, Pavesi L, Parmar V, Regan MM, Pagani O, Fleming GF, Francis PA, Price KN, Coates AS, Gelber RD, Goldhirsch A, Walley BA. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015;16:848–58.

    Article  CAS  Google Scholar 

  23. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL Jr, Gelber RD, Hortobagyi GN, Albain KS. POEMS/S0230 investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923–32.

    Article  CAS  Google Scholar 

  24. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst. 2019;111:210–3.

    Article  Google Scholar 

  25. Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, Meirow D, Pruneri G, Senkus E, Spanic T, Sutliff M, Travado L, Peccatori F, Cardoso F. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203–17.

    Article  Google Scholar 

  26. Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32:2255–69.

    Article  Google Scholar 

  27. Gori S, Puglisi F, Cinquini M, Pappagallo G, Frassoldati A, Biganzoli L, Cortesi L, Fiorentino A, Angiolini C, Tinterri C, De Censi A, Levaggi A, Del Mastro L. Adjuvant endocrine therapy in premeno-pausal patients with hormone receptor-positive early breast cancer: evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM). Eur J Cancer. 2018;99:9–19.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Breast Centre Bern Biel, Hirslanden Campus Bern, Bern, Switzerland

    Patrizia Sager

  2. Division of Gynaecological Endocrinology and Reproductive Medicine, University Women’s Hospital, University of Bern, Bern, Switzerland

    Michael von Wolff

  3. Department of Gynaecology & Obstetrics, Heinrich-Heine University Düsseldorf (HHU), Düsseldorf, Germany

    Tanja Fehm

Authors
  1. Patrizia Sager
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael von Wolff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tanja Fehm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrizia Sager .

Editor information

Editors and Affiliations

  1. Division of Gynaecological Endocrinology and Reproductive Medicine, University Women’s Hospital of Bern, Bern, Switzerland

    Michael von Wolff

  2. Specialist Centre for Reproductive Medicine, Prenatal Medicine, Endocrinology and Osteology, amedes MVZ Hamburg, Hamburg, Germany

    Frank Nawroth

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sager, P., von Wolff, M., Fehm, T. (2020). Breast Cancer. In: von Wolff, M., Nawroth, F. (eds) Fertility Preservation in Oncological and Non-Oncological Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-47568-0_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-47568-0_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-47567-3

  • Online ISBN: 978-3-030-47568-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation